Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsAs a pioneer and undisputed global leader in antibody discovery and manufacture, Creative Biolabs offers Magic™ Therapeutic Antibody Discovery Platform (MTADP) to obtain all possible high affinity antibodies in immunized animals. MTADP is an exclusive high-throughput antibody generation method, especially applicable for therapeutic antibody development with the best manufacturability.
Fig. 1 Selected approved and clinical-stage antibody-based therapeutics for oncology. (Paul J. Carter, 2022)
For diagnostic and therapeutic antibody production, the only way to get good antibodies with all the required properties is to have a large number of antibody candidates first. It is very common that a good antibody pair can only be discovered from 100–300 regular binders raised using different methods in different animals, thus have very diverse properties and sequences. However, traditional hybridoma technology cannot do this job efficiently and cost-effectively.
MTADP is all about time to results: the more antibodies you can get from the screening, the more and more reliable functional antibodies you can send for downstream assessment. Comparing to traditional antibody development using hybridoma, which can only provide several unique antibody sequences for each target, MTADP is more efficient and more promising for functional therapeutic antibody development. Through this powerful platform, a large number of antibody candidates specific to the target can be isolated at one time, in a number of 105-7. Once antibodies targeting different epitopes with different affinity and specificity are obtained, we are able to quickly and precisely identify the clones with the highest affinity and specificity. In combination with our high quality pre-made human antibody libraries, up to 300 unique high specific antibodies with affinities (KD) in the sub 10 pM range against the target are able to be discovered using this exclusive platform. In addition, these antibodies have the best manufacturability for diagnostic and therapeutic applications, overcoming the potential problems of antibody drug development such as protein aggregation, and asparagine deamidation. We guarantee that the endotoxin free antibodies generated are fully functional and ready to use in animal-based assays and clinical trials.
Featured properties of the MTADP service:
Timeline:
Deliverables:
Deliverables for each clone include:
Magic™ Antibody Repertoire Analysis
Magic™ Bioactive Peptide Discovery
Magic™ Peptide Repertoire Analysis
Magic™ BCR Repertoire Analysis
Magic™ TCR Repertoire Analysis
Magic™ Quantitative Immune Repertoire for Small Lymphocytes
Fig. 2 Overall IgM (A) and IgT (B) repertoires across the three torafugu. (Xi Fu, 2018)
Teleost fish are the most primitive bony vertebrates containing immunoglobulins (Igs). This kind of fish has Ig gene rearrangement, junctional diversity during recombination and somatic hypermutation. In this study, scientists chose to analyze and characterize the antibody library of torafugu (Takifugu rubripes) and obtained 1200 million expressed antibody sequences from three healthy adult torafugu. The evidence found in the study shows that, in addition to the convergence and evolution of CDR-H3 sequences in IgM and IgT, the repertoire of individual fish is highly biased towards sequences with specific VDJ combinations. They also observed different components of IgM and IgT, which may indicate different mechanisms for diversity creation in the naïve immune system of fish. The experimental data in this study provide a window for understanding the mechanism of Ig diversity creation and enable scientists to better understand B cell clone selection.
Use the resources in our library to help you understand your options and make critical decisions for your study.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
